Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 5Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Prostatic Neoplasms 4Glioblastoma 4Carcinoma, Renal Cell 4Sarcoma, Alveolar Soft Part 3Sarcoma 3Gliosarcoma 3Fallopian Tube Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Solitary Fibrous Tumor, Pleural 2Mesothelioma, Malignant 2Colorectal Neoplasms 2Carcinosarcoma 2Carcinoma, Ovarian Epithelial 2Brain Neoplasms 2Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Pleural Effusion, Malignant 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neoplasm Metastasis 1

Interventions

atezolizumab 2Etoposide 2Carboplatin 2talazoparib 1olaparib 1lipoarabinomannan 1cediranib 1Specimen Handling 1Platinum 1Magnetic Resonance Spectroscopy 1Lamivudine 1Cisplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Extensive Stage Lung Small Cell Carcinoma × cediranib × Clear all
NCT02899728 2023-10-17

Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
9 enrolled 4 charts

Extensive Stage Lung Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡